Michael A Curran
Overview
Explore the profile of Michael A Curran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
4060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boda A, Bandey I, Chowdhury S, Aggarwal S, Venugopala M, Fowlkes N, et al.
bioRxiv
. 2025 Mar;
PMID: 40060615
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of only 10% in the United States. While immune checkpoint blockade (ICB) has shown efficacy in many solid tumors, PDAC...
2.
Yim S, Lee S, Baek S, Sohn B, Jeong Y, Kang S, et al.
Clin Mol Hepatol
. 2025 Feb;
PMID: 40012401
No abstract available.
3.
Nardo M, Gouda M, Reilley M, Biter A, Lim J, Bean S, et al.
J Immunother Precis Oncol
. 2025 Feb;
8(2):89-98.
PMID: 39959251
Introduction: TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and...
4.
Tang C, Hartley G, Couillault C, Yuan Y, Lin H, Nicholas C, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000133.
PMID: 39886125
Objective: To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with...
5.
DeAzevedo R, Steiner M, Turner B, Liu A, Newton S, Schmidt J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39477243
Blockade of the immune checkpoints programmed death-1 (PD-1) and cytotoxic lymphocyte antigen 4 has improved outcomes for patients with hepatocellular carcinoma (HCC), yet most still fail to achieve objective clinical...
6.
LaPelusa M, Chamseddine S, Tran Cao H, Xiao L, Hasanov E, Bhosale P, et al.
Oncology
. 2024 Oct;
:1-8.
PMID: 39427654
Introduction: Perioperative immunotherapy has shown promise in some patients with early-stage hepatocellular carcinoma (HCC). This study examined tissue and imaging biomarkers associated with pathologic response in a phase II clinical...
7.
Du R, Zhang J, Lukas R, Tripathi S, Ahrendsen J, Curran M, et al.
Neuro Oncol
. 2024 Oct;
27(1):33-49.
PMID: 39427326
The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are...
8.
Deng Y, Zhao Z, Sheldon M, Zhao Y, Teng H, Martinez C, et al.
Nat Metab
. 2024 Aug;
6(9):1756-1774.
PMID: 39147934
Liver regeneration is under metabolic and immune regulation. Despite increasing recognition of the involvement of neutrophils in regeneration, it is unclear how the liver signals to the bone marrow to...
9.
Yim S, Lee S, Baek S, Sohn B, Jeong Y, Kang S, et al.
Clin Mol Hepatol
. 2024 Jul;
30(4):807-823.
PMID: 39038962
Background/aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response...
10.
Najem H, Lea S, Tripathi S, Hurley L, Chen C, William I, et al.
J Clin Invest
. 2024 Jun;
134(12).
PMID: 38941297
STING agonists can reprogram the tumor microenvironment to induce immunological clearance within the central nervous system. Using multiplexed sequential immunofluorescence (SeqIF) and the Ivy Glioblastoma Atlas, STING expression was found...